Offered by: Nemours Children's
Location: Delaware Valley
Efficacy and Safety of Once-Weekly Growth Hormone Compared to Daily Growth Hormone Treatment
We want to do this study to learn more about the effectiveness, safety and treatment satisfaction of a once-weekly growth hormone treatment in children with growth hormone deficiency, compared with once daily human growth hormone treatment.
Children with growth hormone deficiency aged 2-10 years, who have not started puberty and who are about to start treatment with growth hormone injections can be in the study.
In this study, your child will receive either the study drug given once weekly or Norditropin® FlexPro®, given daily. Your child’s participation in the study will last about 157 weeks (36 months and one week). Frequency of visits will occur approximately every one to three months.
There will be 16 blood draws (one per visit), four X-rays and four ECGs throughout the study.
Trial Name: Efficacy and Safety of Once-Weekly Growth Hormone Compared to Daily Growth Hormone Treatment
IRB#: 904884
(800) 354-5690 Email UsLearn more about clinical trials and get answers to questions you might have.
Go to FAQs View All Clinical TrialsNemours has a number of service regions. Selecting your region will help us show you the right contact information and the most relevant content for you.